Many bacteria harbor genes clustered within their genome that encode the machinery to synthesize small molecules called natural products. These clustered genes are call biosynthetic gene clusters (BGCs) and many bacteria harbor 15-30 BGCs in their genome. BGCs have evolved to produce molecules with exquisite potency and selectivity, which has made them attractive and beneficial sources of drug leads. Our lab studies bacteria from marine ecosystems because these bacteria are less well studied compared to their terrestrial counterparts. As a result, the discovery rate of new scaffolds is much higher than traditional terrestrial bacteria.
We have developed mass spectrometry-based metabolomics workflows to assist with designing diversity libraries for high-throughput screening (HTS). See: 1-4 Selection of bacteria for production of small molecules is critical for drug discovery. Random selection of bacteria tends to lead to libraries with high levels of chemical redundancy, which can be a major problem for drug discovery efforts. Additionally, we have leveraged these tools to discover new natural product scaffolds.5-14
We have a major focus on discovery of antifungal and antibacterial natural products. We have developed infrastructure to purify natural products into 96-well plates for HTS. There are two primary reasons for purifying or partially purifying natural products prior to HTS: 1. Crude extracts are 80-90% media components, which masks the activity of natural products; and 2. Bacteria can produce multiple classes of natural products with different pharmacological activities. This work has led to the discovery of many new natural products.12, 15-17